Bazot Quentin, Paschos Kostas, Skalska Lenka, Kalchschmidt Jens S, Parker Gillian A, Allday Martin J
Molecular Virology, Department of Medicine, Imperial College London, London, United Kingdom.
PLoS Pathog. 2015 Jul 8;11(7):e1005031. doi: 10.1371/journal.ppat.1005031. eCollection 2015 Jul.
We show that two host-encoded primary RNAs (pri-miRs) and the corresponding microRNA (miR) clusters--widely reported to have cell transformation-associated activity--are regulated by EBNA3A and EBNA3C. Utilising a variety of EBV-transformed lymphoblastoid cell lines (LCLs) carrying knockout-, revertant- or conditional-EBV recombinants, it was possible to demonstrate unambiguously that EBNA3A and EBNA3C are both required for transactivation of the oncogenic miR-221/miR-222 cluster that is expressed at high levels in multiple human tumours--including lymphoma/leukemia. ChIP, ChIP-seq, and chromosome conformation capture analyses indicate that this activation results from direct targeting of both EBV proteins to chromatin at the miR-221/miR-222 genomic locus and activation via a long-range interaction between enhancer elements and the transcription start site of a long non-coding pri-miR located 28 kb upstream of the miR sequences. Reduced levels of miR-221/miR-222 produced by inactivation or deletion of EBNA3A or EBNA3C resulted in increased expression of the cyclin-dependent kinase inhibitor p57KIP2, a well-established target of miR-221/miR-222. MiR blocking experiments confirmed that miR-221/miR-222 target p57KIP2 expression in LCLs. In contrast, EBNA3A and EBNA3C are necessary to silence the tumour suppressor cluster miR-143/miR-145, but here ChIP-seq suggests that repression is probably indirect. This miR cluster is frequently down-regulated or deleted in human cancer, however, the targets in B cells are unknown. Together these data indicate that EBNA3A and EBNA3C contribute to B cell transformation by inhibiting multiple tumour suppressor proteins, not only by direct repression of protein-encoding genes, but also by the manipulation of host long non-coding pri-miRs and miRs.
我们发现,两种宿主编码的初级RNA(pri-miRs)以及相应的微小RNA(miR)簇——广泛报道具有细胞转化相关活性——受EBNA3A和EBNA3C调控。利用多种携带敲除、回复或条件性EBV重组体的EBV转化淋巴母细胞系(LCLs),能够明确证明EBNA3A和EBNA3C对于致癌性miR-221/miR-222簇的反式激活都是必需的,该簇在多种人类肿瘤(包括淋巴瘤/白血病)中高水平表达。染色质免疫沉淀(ChIP)、ChIP测序和染色体构象捕获分析表明,这种激活是由于两种EBV蛋白直接靶向miR-221/miR-222基因组位点的染色质,并通过增强子元件与位于miR序列上游28 kb处的长链非编码pri-miR的转录起始位点之间的长程相互作用而激活。通过EBNA3A或EBNA3C的失活或缺失产生的miR-221/miR-222水平降低,导致细胞周期蛋白依赖性激酶抑制剂p57KIP2的表达增加,p57KIP2是miR-221/miR-222公认的靶标。miR阻断实验证实,miR-221/miR-222在LCLs中靶向p57KIP2的表达。相反,EBNA3A和EBNA3C对于沉默肿瘤抑制簇miR-143/miR-145是必需的,但此处ChIP测序表明抑制可能是间接的。该miR簇在人类癌症中经常下调或缺失,然而,其在B细胞中的靶标尚不清楚。这些数据共同表明,EBNA3A和EBNA3C通过抑制多种肿瘤抑制蛋白促进B细胞转化,不仅通过直接抑制蛋白质编码基因,还通过操纵宿主长链非编码pri-miRs和miRs来实现。